IRIS

Acrylamide

CASRN 79-06-1

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (34 pp, 324 K) last updated: 03/22/2010

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Nervous 2 x 10-3 Degenerative nerve changes HED (BMDL): 0.053
mg/kg-day
30 Medium/High

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (34 pp, 324 K) last updated: 03/22/2010

System RfC (mg/m3) Basis PoD Composite UF Confidence
Nervous 6 x 10-3 Degenerative nerve changes HEC5 (BMDL): 0.18
mg/m3
30 Medium

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (34 pp, 324 K) last updated: 03/22/2010

WOE Characterization Framework for WOE Characterization
Likely to be carcinogenic to humans Guidelines for Carcinogen Risk Assessment (US EPA, 2005)
Basis:
  • In accordance with the Guidelines for Carcinogen Risk Assessment U.S. EPA, 2005, acrylamide (AA) is characterized as "likely to be carcinogenic to humans."
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (34 pp, 324 K)

Oral Slope Factor: 5 x10 -1 per mg/kg-day
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
Tumor site(s): Reproductive, Endocrine
Tumor type(s): thyroid tumors and tunica vaginalis mesotheliomas (Johnson et al., 1986)
Note: ADAF -- EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure.



Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (34 pp, 324 K)

Inhalation Unit Risk: 1 x10 -4 per µg/m3
Extrapolation Method: Multistage model with linear extrapolation from the point of departure (BMDL), summed risk.
Tumor site(s): Reproductive, Endocrine
Tumor type(s): thyroid tumors and tunica vaginalis mesotheliomas (Johnson et al., 1986)
Note: ADAF -- EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure.


You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.